Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Atopic Hand and Foot Dermatitis at AAD 2023
- The P-III trial evaluating Dupixent (200/300mg, q2w) in 133 adolescents & adults with mod. to sev. atopic hand & foot dermatitis
- The trial met its 1EPs & 2EPs i.e., patients achieved clear or almost clear skin on hands & feet (40% vs 17%), 52% vs 14% reduction in itch on hands & feet, 69% vs 31% avg. reduction in signs of hand & foot lesions from baseline, 75% vs 40% improvement in hand eczema disease severity from baseline along with significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related QoL
- The safety results were similar to the known safety profile of Dupixent, overall rates of AEs (66% vs 74%), patients used one rescue medication (3% vs 21%)
Ref: GlobeNewswire | Image: Regeneron
Related News:- Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA of Dupixent (dupilumab) for Chronic Spontaneous Urticaria in Adults and Adolescents
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].